EphA3 was subsequently found to be widely expressed also in myeloid malignancies [63,64], and in tumors of mesenchymal origin, such as melanoma, sarcoma and glioblastoma, where it is particularly associated with a more mesenchymal phenotype, and progenitor or stem cell-like tumor cells [49]. The gene discussed is EPHA3; the disease is melanoma.